Inhibrx Balans Gezondheid
Financiële gezondheid criteriumcontroles 5/6
Inhibrx has a total shareholder equity of $11.6M and total debt of $208.2M, which brings its debt-to-equity ratio to 1799.9%. Its total assets and total liabilities are $288.6M and $277.0M respectively.
Belangrijke informatie
1,799.9%
Verhouding schuld/eigen vermogen
US$208.21m
Schuld
| Rente dekkingsratio | n/a |
| Contant | US$252.48m |
| Aandelen | US$11.57m |
| Totaal verplichtingen | US$277.01m |
| Totaal activa | US$288.58m |
Recente financiële gezondheidsupdates
Recent updates
Inhibrx: Continued Advancement Even After INBRX-101 Sale To Sanofi
Jun 07Is Inhibrx (NASDAQ:INBX) Using Debt Sensibly?
May 13
Inhibrx down 8% after announcing webcast for pathway for rare disease candidate
Oct 03Inhibrx: Potential To Move To Registration Study With INBRX-101
Jun 10Inhibrx, Inc. (NASDAQ:INBX) Shares Could Be 38% Below Their Intrinsic Value Estimate
Mar 23Analyse van de financiële positie
Kortlopende schulden: INBX's short term assets ($274.5M) exceed its short term liabilities ($71.9M).
Langlopende schulden: INBX's short term assets ($274.5M) exceed its long term liabilities ($205.1M).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: INBX has more cash than its total debt.
Schuld verminderen: INBX had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balans
Analyse van de cashflow
Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.
Stabiele cash runway: INBX has sufficient cash runway for more than a year based on its current free cash flow.
Voorspelling contante baan: INBX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 38.9% each year